Lactoferrin combined with Bifidobacterium animalis subsp. lactis BB-12 improves respiratory tract infections.
Lactoferrin combined withsubsp.BB-12 improves respiratory tract infections and modulates Gut microbiome function in children: a randomized, double-blind, placebo-controlled trial.
AI Summary
Key Findings
Abstract
OBJECTIVES AND STUDY: To explore the effects and mechanisms of lactoferrin combined withsubsp.BB-12 on Respiratory tract infections (RTIs) in healthy children through a randomized, double-blind, placebo-controlled trial. METHODS: Eligible healthy children aged 0-6 years were randomized into intervention group (IG, = 60, receiving lactoferrin and probiotic for 3 months) and control group (CG, = 34, receiving placebo). The study primarily assessed changes in the incidence and severity of RTIs, and monitored gastrointestinal adverse events. Fecal samples were collected pre- and post-intervention to analyze gut microbiota composition and metabolomic profiles, including short-chain fatty acids (SCFAs). RESULTS: After the intervention, the incidence of RTIs showed no significant difference between groups (55% vs. 61.8%, = 0.52), but both the RTI severity score (3.0 vs. 4.0,
Affiliation
Zhe Shi
External References
- PubMed ID:
- 42038244
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.